70,000 Ebola Vaccine Doses Sent to Democratic Republic of Congo Amid Outbreak

The Democratic Republic of Congo has received 70,000 doses of the Ervebo vaccine to combat an ongoing Ebola outbreak caused by the Bundibugyo virus, according to UN reports. While Ervebo is licensed and recommended for outbreaks of the Zaire ebolavirus, its efficacy against the Bundibugyo strain remains uncertain. This uncertainty necessitates further investigation, with 20,000 of the allocated doses designated for Phase 3 clinical trials. These trials aim to determine how effective the vaccine is against the rapidly spreading Bundibugyo virus in the DRC. The remaining 50,000 doses are intended for healthcare workers and other personnel on the front lines of the outbreak response, aligning with recommendations from the WHO's Strategic Advisory Group of Experts. Preliminary laboratory and animal studies suggest Ervebo may offer some protection against the Bundibugyo virus, but human efficacy data is still lacking. The clinical trial is expected to yield crucial information for future vaccination decisions. The WHO emphasizes that all participants, whether in the trial or receiving the vaccine outside of it, will be fully informed about potential risks, benefits, and limitations. Consent will be a prerequisite for vaccination. The current Ebola outbreak was declared by DRC health authorities on May 15, and two days later, the WHO recognized it as a public health emergency of international concern. The outbreak has resulted in over 2,000 deaths, with a case fatality rate nearing 47 percent.

“

Preliminary laboratory studies and animal studies show that Ervebo may provide some protection against the Bundibugyo virus. However, there is currently no data on its effectiveness in humans.